City of Hope scientists combine oncolytic virus and CAR T in solid tumors

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

City of Hope scientists have combined two immunotherapies—an oncolytic virus and chimeric antigen receptor CAR T-cell therapy—to target and eradicate solid tumors that are otherwise difficult to treat with CAR T therapy alone, according to a study in Science Translational Medicine.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe

YOU MAY BE INTERESTED IN

When conducting a randomized clinical trial of a treatment regimen based on an immune checkpoint inhibitor, trial sponsors should include overall survival as an endpoint, FDA officials say.

Login